What is Tamiflu?
Tamiflu (oseltamivir) is an oral neuraminidase inhibitor with EU authorisation for specified influenza treatment and prevention uses. It acts against influenza A and B, not every illness with flu-like symptoms.
Authorisation and treatment recommendations differ. WHO’s 2024 guideline strongly recommends against oseltamivir and zanamivir for non-severe influenza. It conditionally supports oseltamivir for severe influenza, with very low-certainty evidence. US CDC guidance dated March 2026 recommends prompt antiviral treatment for hospitalised, severe/progressive or higher-risk patients and allows selected early outpatient treatment. These are attributed recommendations, not a new Spanish prescribing policy. A clinician must apply the relevant official guidance, local epidemiology and individual circumstances.
How does Tamiflu work?
Oseltamivir is converted in the body to oseltamivir carboxylate. This active metabolite inhibits viral neuraminidase, limiting release and spread of newly formed influenza particles. At least 75% of the oral dose reaches systemic circulation as the active metabolite; this is not the same measurement as inhaled zanamivir absorption.
Early treatment can shorten symptoms in clinical trials. It does not guarantee a particular recovery time or prevention of serious complications. In severe influenza, WHO describes substantial uncertainty about effects on mortality and intensive-care admission.
Who is Tamiflu for?
Treatment: The Spanish label includes adults and children, including full-term newborns, with typical symptoms when influenza is circulating. The label’s start window is within 48 hours of symptoms.
Risk assessment: Older adults aged 65 years and over, immunocompromised people, patients with chronic respiratory, cardiovascular, renal, hepatic or metabolic disease, and pregnant or postpartum women need prompt assessment. CDC prioritises high-risk patients; the label itself does not firmly establish efficacy in immunosuppression or treatment efficacy in chronic cardiac/respiratory disease. These distinctions must not become a promise of benefit.
Prevention: Post-exposure use from age 1 year is assessed case by case and starts within 48 hours of contact. Below 1 year, the Spanish indication is specifically post-exposure prevention during a pandemic. Exceptional seasonal prevention is separate; it is not automatic after any contact.
Late presentation: CDC recommends prompt oseltamivir for hospitalised or severe/progressive influenza, including selected patients presenting more than 48 hours after onset. This US guidance does not alter the labelled routine start window or create a Spanish protocol. Seek care even if the window has passed.
Dosage
These are Spanish label schedules, not a decision that treatment is appropriate. Follow the actual prescription.
Treatment
| Group | Dose | Frequency | Duration |
|---|---|---|---|
| Adults and adolescents (≥13 years; standard regimen) | 75 mg | Twice daily | 5 days |
| Immunocompromised adults and adolescents (≥13 years; standard regimen) | 75 mg | Twice daily | 10 days |
| Children (1–12 years) | Weight-based dose prescribed by clinician | Twice daily | 5 days; 10 days if immunocompromised |
| Full-term infants below 1 year | Age- and weight-specific prescription | Twice daily | 5 days; 10 days if immunocompromised |
| Kidney impairment | Individual renal adjustment | As prescribed | Individual clinical assessment |
Prevention
| Group | Dose | Frequency | Duration |
|---|---|---|---|
| Adults and adolescents (≥13 years; post-exposure) | 75 mg | Once daily | 10 days |
| Adults and adolescents (seasonal prevention) | 75 mg | Once daily | Up to 6 weeks |
| Immunocompromised adults and adolescents (seasonal prevention) | 75 mg | Once daily | Up to 12 weeks |
Paediatric prevention is age- and weight-specific; the adult table must not be used for children. Premature infants and children with kidney impairment need specialist assessment because the routine schedules do not cover them. Adults and adolescents with impaired kidney function may need changes to both dose and frequency, for treatment and prevention.
The product information lists capsules of 30 mg, 45 mg and 75 mg and a 6 mg/mL oral suspension. This concentration is not a statement of stock or supply. Check the dispensed concentration and the prescribed volume with the pharmacist; do not use an old suspension concentration or improvise preparation. Food may reduce nausea and vomiting.
Side effects
Very common and common effects
Nausea and headache are very common in adults and adolescents; vomiting and abdominal pain are common. Vomiting is very common in children. Frequencies depend on the age group. Gastrointestinal symptoms often begin early and may settle, but persistent symptoms or dehydration require assessment.
Serious risks
- Neuropsychiatric events: Confusion, abnormal behaviour, hallucinations and delirium have been reported, especially in children and adolescents. Influenza itself can cause these events without oseltamivir. Monitor closely and seek prompt help for behavioural changes.
- Serious skin reactions: Rare reactions include Stevens–Johnson syndrome and toxic epidermal necrolysis. Stop and seek urgent medical care for blistering rash or mucosal lesions.
- Anaphylaxis and swelling: These are rare in the label, not “very rare”. Stop treatment and seek emergency help for breathing difficulty, facial or tongue swelling.
- Liver injury or gastrointestinal bleeding: Rare serious reactions are reported; jaundice, blood in the stool or black stool need urgent assessment.
Tamiflu and Relenza
| Feature | Tamiflu (oseltamivir) | Relenza (zanamivir) |
|---|---|---|
| Route | Oral | Inhaled through Diskhaler |
| Treatment age in Spanish product information | Includes full-term newborns | 5 years and over |
| Respiratory considerations | Individual assessment; oral administration | Bronchospasm risk; special asthma/COPD precautions |
| Formulation | Capsule or oral suspension | Inhalation powder |
| Important adverse effects | Nausea, vomiting and serious hypersensitivity | Bronchospasm and hypersensitivity |
This comparison does not establish a preferred treatment for everyone. The route alone cannot determine suitability.
Online assessment for Tamiflu (Oseltamivir)
Seek assessment promptly, especially if you have risk factors or worsening symptoms. Urgent breathing difficulty or deterioration needs urgent care, not a wait for an online prescription. More than 48 hours since onset does not mean it is too late to seek help.
Prescrivia is a technology intermediary connecting patients with independent doctors and licensed pharmacies. We do not provide medical services, prescribe, employ doctors, sell or dispense medicines.
- Assessment: Provide your symptoms or travel plans, medical history and all current medicines.
- Independent review: A doctor decides whether a prescription is clinically appropriate; Prescrivia does not guarantee a prescription.
- Dispensing: Any lawful dispensing is the responsibility of a licensed pharmacy, subject to the applicable rules and product availability.
In Spain, distance selling of prescription medicines is prohibited. An online assessment or a product label does not establish that a medicine can legally be supplied or delivered through this platform. This information does not change eligibility or fulfilment rules.
Important safety information
Do not take Tamiflu if you are allergic to oseltamivir or any excipient.
Tell your doctor about kidney disease, pregnancy or breastfeeding and all other medicines. Probenecid and medicines with a narrow safety margin cleared by renal tubular secretion, such as methotrexate, need consideration. Children require the prescribed age- and weight-specific dose and careful measurement of the actual formulation.
Watch for unusual behaviour, confusion or hallucinations, particularly in children. Seek urgent care for severe skin reactions, swelling or worsening breathing.
Vaccination: Tamiflu does not replace influenza vaccination. Follow official vaccination recommendations.
Resistance: Susceptibility varies by season and location. Historical label data do not establish the susceptibility of strains currently circulating in Spain; the clinician must consider current surveillance and official recommendations.
Sources
- AEMPS: Tamiflu, sections 4.1–4.8 and 5.1–5.2.
- AEMPS: Relenza, sections 4.1–4.4.
- WHO 2024: non-severe influenza, sections 7.1.4 and 7.1.7.
- WHO 2024: severe influenza, section 8.1.1.
- CDC: antiviral guidance, March 2026.
- BOE: Article 3.5.
This information does not replace advice from a qualified healthcare professional.
Frequently asked questions
- What is Tamiflu used for?
- Spanish product information covers influenza treatment in adults and children, including full-term newborns. Routine post-exposure prevention starts from age 1 year; prevention below that age has a separate pandemic indication. Start assessment promptly: the label specifies treatment within 48 hours of symptoms, but later presentation is not a reason to avoid medical care.
- How much does Tamiflu shorten the duration of flu?
- Trials show some shortening of symptoms with early treatment, but benefit varies by population. WHO's 2024 guideline recommends against oseltamivir for non-severe influenza and conditionally supports it for severe disease with very low-certainty evidence. It is not a guarantee of avoiding pneumonia or hospitalisation; CDC recommendations differ.
- Can I take Tamiflu to prevent flu after being exposed?
- A doctor decides case by case. In adults and adolescents aged 13 years and over, the labelled post-exposure regimen is 75 mg once daily for 10 days, started within 48 hours of contact. The amount per dose is the same as standard adult treatment, but the frequency differs. Children need age- and weight-specific instructions. It does not replace vaccination.
- What are the main side effects of Tamiflu?
- Nausea and headache are very common in adults and adolescents; vomiting is very common in children. Food may improve tolerability. Serious allergic, skin and neuropsychiatric reactions are also reported. Seek help for unusual behaviour, severe rash, swelling or breathing difficulty.
- Is Tamiflu suitable for people with asthma or COPD?
- Oral oseltamivir does not have the inhaled-powder administration risk of Relenza. However, suitability needs medical assessment: the label does not establish treatment efficacy in chronic cardiac or respiratory disease. US CDC guidance prioritises high-risk patients, but this is not a blanket recommendation for every person with asthma or COPD.
Related treatments
Compare related options in the same wider treatment route.
Intermediary notice: Prescrivia connects patients with independent doctors and licensed pharmacies. We do not provide medical advice, employ doctors, or sell medicines. All medical decisions are made by independent healthcare professionals, and prescription-only medicines require a valid prescription. Treatment is not guaranteed — whether a prescription is issued depends on an independent doctor's clinical assessment.
Current review status is not yet confirmed. Enable JavaScript to load current review records.